Primary mediastinal B-cell lymphoma · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pembrolizumab monotherapy Variant #01 | — | R 286 955 | 14d | ~13.2 mo | — | ~29 | ~R 8 321 703 PFS proxy · indirect | 1 |
Axicabtagene ciloleucel monotherapy N/A - secondary systemic drug | — | R 0 | — | — | — | — | — | 1 |
Lisocabtagene maraleucel monotherapy Variant #01 Partial | — | — | — | — | — | — | — | — |
3 of 3 regimens shown